I am a
Home I AM A Search Login

Papers of the Week

Papers: 23 Nov 2019 - 29 Nov 2019

Human Studies, Pharmacology/Drug Development


2020 May

Clin Transl Sci



Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase 2b Clinical Trials of Ubrogepant for Migraine Treatment.


Li C-C, Voss T, Kowalski K, Yang B, Kleijn H J, Jones CJ, Bosch R, Michelson D, DeAngelis M, Xu Y, Xie I, Kothare PA
Clin Transl Sci. 2020 May; 13(3):482-490.
PMID: 31758661.


Ubrogepant (MK-1602) is a novel, oral, calcitonin gene-related peptide receptor antagonist in clinical development with positive Phase III outcomes for acute treatment of migraine. This paper describes the population exposure-response (E-R) modeling and simulations which were used to inform the Phase III dose-selection rationale, based on approximately 800 participants pooled across two Phase IIb randomized dose-finding clinical trials. The E-R model describes the placebo and ubrogepant treatment effects based on migraine pain endpoints (2-hour pain relief and 2-hour pain freedom) at various dose levels. Sensitivity analyses were conducted to evaluate various assumptions of placebo response in light of the high placebo response observed in one Phase II trial. A population PK model describing the effect of formulations was included in the E-R simulation framework to assess potential dose implications of a formulation switch from Phase II to Phase III. Model-based simulations predict that a dose of 25 mg or higher is likely to achieve significantly better efficacy than placebo with desirable efficacy levels. The understanding of E-R helped support the dose selection for the Phase III clinical trials.